Loading...

Stevanato Group S.p.A.

STVNNYSE
Healthcare
Medical - Instruments & Supplies
$22.62
$-0.23(-1.01%)

Stevanato Group S.p.A. (STVN) Financial Performance & Income Statement Overview

Analyze Stevanato Group S.p.A. (STVN) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
1.72%
1.72%
Operating Income Growth
-19.72%
19.72%
Net Income Growth
-19.13%
19.13%
Operating Cash Flow Growth
48.06%
48.06%
Operating Margin
16.06%
16.06%
Gross Margin
28.04%
28.04%
Net Profit Margin
11.75%
11.75%
ROE
9.71%
9.71%
ROIC
9.83%
9.83%

Stevanato Group S.p.A. (STVN) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Stevanato Group S.p.A. STVN financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$256.60M$330.60M$277.87M$259.58M
Cost of Revenue$186.71M$232.44M$203.42M$196.20M
Gross Profit$69.89M$98.15M$74.44M$63.38M
Gross Profit Ratio$0.27$0.30$0.27$0.24
R&D Expenses$5.93M$5.57M$6.61M$8.74M
SG&A Expenses$29.44M$31.26M$27.65M$31.75M
Operating Expenses$35.26M$31.30M$33.42M$42.25M
Total Costs & Expenses$221.97M$263.74M$236.84M$231.61M
Interest Income$360000.00$81000.00$584425.00$974000.00
Interest Expense$1.43M$2.96M$1.74M$837000.00
Depreciation & Amortization$20.62M-$22.81M$60.95M$20.85M
EBITDA$57.16M$67.61M$103.32M$50.85M
EBITDA Ratio$0.22$0.20$0.37$0.20
Operating Income$34.63M$66.86M$41.03M$27.97M
Operating Income Ratio$0.13$0.20$0.15$0.11
Other Income/Expenses (Net)$481000.00-$2.21M-$237000.00$1.35M
Income Before Tax$35.11M$64.65M$40.79M$29.32M
Income Before Tax Ratio$0.14$0.20$0.15$0.11
Income Tax Expense$8.60M$16.34M$10.77M$8.55M
Net Income$26.52M$48.31M$30.03M$20.63M
Net Income Ratio$0.10$0.15$0.11$0.08
EPS$0.10$0.18$0.11$0.08
Diluted EPS$0.10$0.18$0.11$0.08
Weighted Avg Shares Outstanding$272.90M$272.87M$272.87M$272.79M
Weighted Avg Shares Outstanding (Diluted)$272.91M$272.88M$272.88M$272.81M

Over the last four quarters, Stevanato Group S.p.A. achieved steady financial progress, growing revenue from $259.58M in Q2 2024 to $256.60M in Q1 2025. Gross profit stayed firm with margins at 27% in Q1 2025 versus 24% in Q2 2024. Operating income totaled $34.63M in Q1 2025, maintaining a 13% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $57.16M. Net income dropped to $26.52M, with EPS at $0.10. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;